tbuckley/cabot-search huggingface dataset:
SP0146 Drugs Causing Muscle Disease
Authors: A. Mammen
Journal: Annals of the Rheumatic Diseases (2015)

Many drugs prescribed by physicians have the potential to cause muscle damage. Among the most common of these are statin medications. Although statins are effective at reducing the risk of life-threatening cardiovascular and cerebrovascular disease, they may cause mild muscle symptoms without weakness or CK elevations in 5-10% of those who take them. In a small number of cases, patients may experience mild to moderate weakness and/or CK elevations. And very rarely, patients may develop severe rhabodomyolysis as a result of statin exposure. In most cases, statin toxicity is self-limited and stopping the statin results in resolution of the symptoms within days to months. Frequently, a different statin or the same statin at a lower dose may be restarted and will be tolerated well by the patient. However, some patients are not able to tolerate an effective dose of any statin. Various factors predispose patients to self-limited statin intolerance, including statin dose, other prescribed medications, and genetic susceptibility. Very rarely, statin exposure is associated with an autoimmune myopathy with autoantibodies recognizing anti-HMG-CoA reductase; patients with self-limited statin toxicity do not have anti-HMG-CoA reductase autoantibodies. Patients with autoimmune statin myopathy generally have proximal muscle weakness, marked CK elevations (mean peak CK of around 10,000 IU/L), and muscle biopsies with prominent necrosis and minimal lymphocytic infiltrates. Once this process is initiated, the myopathy progresses even after the statin is discontinued and treatment with immunosuppressive agents is required to control the disease. Many patients with statin-associated anti-HMG-CoA reductase myopathy need treatment with multiple agents to achieve remission. The disease often flares with tapering of immunosuppression or statin re-challenge. Other myotoxic medications include colchicine, hydroxychloroquine, and high dose prednisone. Fortunately, myopathies associated with these drugs will resolve with discontinuation of the offending drug. <h3>Disclosure of Interest</h3> None declared
Clinicopathologic Features of Advanced Squamous NSCLC
Authors: Mark A. Socinski, Coleman Obasaju, David Gandara, Fred R. Hirsch, Philip Bonomi, Paul Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz-Ares, Maurice Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Thomas E. Stinchcombe, Heather Wakelee, Carlos Mayo, Nick Thatcher
Journal: Journal of Thoracic Oncology (2016)
Naming Names
Authors: A B Weisse
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diminished Multi-Organ Pathologies and Inflammation Associated With Sickle Cell Disease In Mice With Genetically Limited Prothrombin Levels
Authors: Paritha Arumugam, Eric S. Mullins, Maureen A Shaw, Kumar Shanmukhappa, Anastacia Loberg, Tilat Rizvi, Janaka Wansapura, David Witte, Punam Malik, Jay L. Degen
Journal: Blood (2013)
Increase in Liver Cancer
Authors: Clemmesen, Johannes
Journal: JNCI Journal of the National Cancer Institute (1981)

Journal Article Increase in Liver Cancer Get access Johannes Clemmesen Johannes Clemmesen Stockholmsgade 43 DK 2100 Copenhagen 0, Denmark Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 67, Issue 1, July 1981, Pages 3–4, https://doi.org/10.1093/jnci/67.1.3-a Published: 01 July 1981
Parents' attitudes and patients' behavior: a prospective study
Authors: D A Greenman, J G Gunderson, D Canning
Journal: American Journal of Psychiatry (1989)

The authors studied the behavior of 67 psychiatric inpatients and the attitudes of their parents toward their hospitalization. They found that certain parental concerns at admission correlated with particular aspects of patient behavior and ability to engage in treatment during the first 6 weeks of hospitalization. These findings have implications for the management of inpatient treatment.
Safety of the combination of lithium and neuroleptic drugs
Authors: R D Goldney, N D Spence
Journal: American Journal of Psychiatry (1986)

A retrospective study of 60 manic patients treated with neuroleptic medications alone and 69 manic patients treated with a combination of neuroleptic drugs and lithium revealed no difference between groups in side effects and complications of treatment. Similarly, when comparisons were made between patients treated with haloperidol only and those treated with haloperidol and lithium, there were no differences in side effects and complications. The results counter sporadic clinical reports suggesting a toxic interaction between lithium and neuroleptic drugs.
&lt;emph type="ital"&gt;Penumbra&lt;/emph&gt;
Authors: Thomas B. Cole
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Case 7-1968
Authors: Alfred Kranes, Robert E. Scully
Journal: New England Journal of Medicine (1968)

Presentation of Case First admission. A seventy-five-year-old chemist was admitted to the hospital because of malaise.Fifty years previously he had undergone an appendectomy at home. For many years thereafter intermittent episodes of a vague aching sensation in the right lower quadrant of the abdomen occurred two or three times per year. Thirty years before entry painless, mild jaundice developed and cleared spontaneously in about ten days. At that time there was the onset of intermittent attacks of colitis, continuing over a period of fifteen to twenty years, with diarrhea and right-lower-quadrant discomfort; the diarrhea was controlled with bismuth. On . . .
Mesmerism in New Orleans, 1845–1861
Authors: Wallace K. Tomlinson, J. John Perret
Journal: American Journal of Psychiatry (1974)

Mesmerism was generally rejected by the medical establishment in Europe and the United States until Jean-Martin Charcot introduced it at the Salpêtriѐre in the 1870s. Nonetheless, a well-organized and active mesmer society flourished in New Orleans from 1845 to 1861. The origins of the society, composition of the memhership, its activities, and its relationship with the established medical community are presented.
Feasibility and Optimal Schedule Of Using Eculizumab In Patients With Hemolytic Paroxysmal Nocturnal Hemoglobinuria (hPNH) With Severe Aplastic Anemia (SAA) Prior To Haemopoietic Stem Cell Transplant (HSCT)
Authors: Austin G Kulasekararaj, Victoria T Potter, Shreyans A Gandhi, Nana benson-Quarm, Joanna Large, Antonio Pagliuca, Ghulam J. Mufti, Judith Marsh
Journal: Blood (2013)
A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment.
Authors: Ryan J. Sullivan, Jeffrey S. Weber, Sapna Pradyuman Patel, Reinhard Dummer, Wilson H. Miller, David Cosgrove, Matteo S. Carlino, Daniel Shao-Weng Tan, Celeste Lebbe, Tiziana Cipani, Elena Élez, Heiko Maacke, Panagiotis Nikolopoulos, Mounir Aout, Laure A. De Parseval, Paolo Antonio Ascierto
Journal: Journal of Clinical Oncology (2015)

9007 Background: MEKi addition to BRAFi therapy has been reported to increase response rate (RR) and duration of response. The BRAFi ENCO (LGX818) and MEKi BINI (MEK162) have each shown promising single-agent activity in BRAFV600–mutant melanoma. Methods: Combined ENCO and BINI are being evaluated in this phase (Ph) Ib/II open-label study of patients (pts) with BRAFV600–mutant cutaneous melanoma. Based on Ph Ib dose-escalation findings, the safety and efficacy of ENCO 600 mg or 450 mg daily + BINI 45 mg twice daily are being investigated in the Ph II part of the study. Results: Fifty-five BRAFi-naive pts were enrolled in Ph Ib (n = 13) or Ph II (n = 42). Median duration of exposure was 9.7 mo; 9 pts received ENCO 400 mg or 450 mg daily (5 in Ph Ib, 4 in Ph II), and 39 pts received ENCO starting at 600 mg daily (1 in Ph Ib, 38 in Ph II), all with BINI. Among all pts starting at ENCO 600 mg, common adverse events (AEs; all grades [Grs] > 30%) were nausea (54%), diarrhea (44%), fatigue and arthralgia (33% each), and vomiting, pyrexia, and increased AST (31% each). At ENCO 400/450 mg, rates of these AEs were: nausea and fatigue (44% each), diarrhea, vomiting, and increased AST (33% each), and arthralgia and pyrexia (11% each). Gr 3/4 AEs occurred in 64% of pts treated with 600 mg, commonly including increased ALT (18%), lipase (15%), AST (13%), and creatine phosphokinase (13%). At 400/450 mg, Gr 3/4 AEs occurred in 67% of pts; increased lipase (22%) was the only event occurring in > 1 pt. Photosensitivity (n = 1, 400 mg; n = 1, 600 mg) and Gr 3/4 pyrexia (n = 2, 600 mg) were rare. The confirmed RR among pts treated at ENCO 400/450 mg was 78% (1 CR + 6 PRs) and at ENCO 600 mg was 72% (3 CRs + 25 PRs). Ph Ib and Ph II combined (all doses) median progression-free survival (95% CI) was 11.3 (7.4-14.6) mo, and in pts with baseline lactate dehydrogenase (LDH) > upper limit of normal (ULN; n = 21) and ≤ ULN (n = 32), was 6.8 (5.0-11.3) mo and 20.0 (11.0-not reached) mo, respectively. Conclusions: These data suggest that ENCO + BINI is well tolerated at multiple doses, with promising activity in BRAFi-naive pts with BRAF-mutant melanoma. A Ph III trial (COLUMBUS) is underway using ENCO 450 mg daily with BINI. Clinical trial information: NCT01543698.
68Ga DOTATATE PET/CT of Synchronous Meningioma and Prolactinoma
Authors: Sandip Basu, Rohit Ranade, Suman Hazarika
Journal: Clinical Nuclear Medicine (2015)

68Ga DOTATATE PET/CT in noninvasive characterization of synchronous pituitary neoplasm and meningioma in a 38-year-old man is illustrated. The patient presented with an MRI-detected lobulated enhancing sellar-suprasellar mass with erosion of bony sella measuring 4.5 × 3.5 × 3.4 cm (with differential diagnosis with germ cell tumor) and a right parafalcine mass (2.7 × 2.6 cm) suggesting meningioma. 68Ga DOTATATE PET/CT demonstrated intense uptake in both lesions, suggesting the sellar mass to be pituitary macroadenoma. The finding of high serum prolactin and normal LH, FSH, cortisol, and testosterone levels suggested diagnosis of prolactinoma, and the patient was started on cabergoline.
PWE-355 Ct-colonography use in incomplete colonoscopy and frail patients
Authors: U Pisano, D Eason, E Semple, A Banerjee, J Docherty, M Lim, AJ Watson
Journal: Gut (2015)

<h3>Introduction</h3> CT-colonography (CTC) is a valid alternative to standard colonoscopy in colorectal cancer (CRC). In the context of screening, it is employed only in unsuitable colonoscopy candidates or when colonoscopy is incomplete. With rising numbers in both categories, the use of CTC within our NHS Board has increased over 300% in the last 5 years. <h3>Method</h3> 198 consecutive patients who underwent CTC between January 2013–October 2013 were retrieved from a prospectively collected radiology database. Patient who had a CTC were allocated into one of two groups; (1) patients who were “frail,” with cardiovascular, pulmonary, renal impairment or generalised poor mobility or (2) they had an “incomplete” colonoscopy. We analysed the characteristics of the two groups, colonic findings and follow-up rates. Statistical analysis of categorical variables was performed using Chi-square. Differences in mean were sought with the t-test. A p-value &lt;0.05 was considered significant. <h3>Results</h3> 116 patients were allocated in the “incomplete” group (M/F: 49/67) and 82 in the “frail” group (M/F: 42/40) (p = 0.27). Mean age was 71 (SD±10) for the “incomplete” group and 72 (SD±12) in the “frail” group (p = 0.51). Isolated and multiple polyps were found in 22 “incomplete” colonoscopy and 14 “frail” patients (11.2% and 7.1%)(p = 0.91): The polyp size was recorded as: 13 cases (6.6%) were &lt;5mm (diminutive), 20 cases (10.1%) between 6–9mm (small) and 13 cases were ≥ 10mm (large). There was no association between polyp size and patient group (p = 0.6, 1.0 and 0.7) and no age difference for polyp sizes (p = 0.89, 0.45, 0.36). 20 colonoscopies (10.1% of total) were subsequently performed after the CTC in the “failed” group and 17 (8.6%) in the “frail” group, with no difference between the groups (p = 0.66). <h3>Conclusion</h3> There are no significant difference in lesion and polyp yield between those who “failed” to complete optical colonoscopy and those deemed too “frail” to undergo the endoscopic investigation. The increasing trend for referral for CTC reflects the wider requirement to investigate the elderly and frail population by an established and refined technique. We have increased the use of CTC in our Board, due to a continued decease in use of barium enemas, the need to rule out cancer in patients who are too frail to undergo surgery and an increased confidence in the technique by referrers, after evidence of the equivalence of CTC with colonoscopy. Whilst optical colonoscopy numbers are still climbing significantly as a result of bowel screening, a similar trend for CTC-based screening might be observed in the next years. In our groups of patients, there was no difference in the colonoscopy rate after CTC. <h3>Disclosure of interest</h3> None Declared.
SAT0409 The New ERA of Anti-Phospholipid Antibodies: from Immunoenzymatic to Chemiluminescence Methods
Authors: M. Fabris, N. Tanzi, R. Giacomello, M. Marangone, F. Curcio, E. Tonutti
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The laboratory arm of the diagnostic process of the anti-phospholipid antibodies (aPL) syndrome is facing a crucial moment of renewal thanks to the availability both of new serological biomarkers and of new analytical methods. <h3>Objectives</h3> To compare the analytical performance of immunoenzymatic (ELISA) and chemiluminescence (CLIA) aPL tests during twelve months of observation. <h3>Methods</h3> We collected data on aCL (anti-cardiolipin), aB2GPI (anti-B2-glycoprotein I) IgG and IgM antibodies of 2628 patients, referred to our diagnostic Laboratory from October 2013 to October 2014. From October 2013 to may 2014 anti-phospholipid (aPL) antibodies were analysed by ELISA (Orgentec, Idk; cut-off aCL IgG &gt;10 U/ml, aCL IgM &gt;8 U/ml, aB2GPI IgG/IgM &gt;8 U/ml) while from june 2014 to October 2014 they were analysed by CLIA (Zenit RA, Menarini Diagnostics; cut-off IgG &gt;20 U/ml, IgM &gt;10 U/ml). Lupus anticoagulant (LAC) assays were done in all cases following standardized methods. <h3>Results</h3> By ELISA we found 61/1625 (3.8%) aCL IgG+ patients, among which 36 (59%) were also aB2GPI IgG+, and 108/1625 (6.6%) aCL IgM+ patients, among which 89 (82.4%) also B2GPI IgM+. On the other hand, among the overall 57/1625 (3.5%) aB2GPI IgG+ patients, 36 (63.2%) were also aCL IgG+ and among the overall 106/1625 (6.5%) aB2GPI IgM+ patients, 89 (83.9%) were also aCL IgM+. However, when considering aB2GPI IgG or IgM &gt;40 U/ml, 100% of positive aB2GPI samples were also aCL positive. By CLIA, we found 38/1003 (3.8%) aCL IgG+ patients, among which 37 (97.4%) also aB2GPI IgG+ and 125/1003 (12.5%) aCL IgM+ patients, among which 100% were also aB2GPI IgM+. Furthermore, among the overall 42/1003 (4.2%) aB2GPI IgG+ patients, 40 (95.2%) were also aCL IgG+, while among the overall 163/1003 (16.3%) aB2GPI IgM+ patients, 127 (77.9%) were also aCL IgM+. Again, when considering only high IgG+ or IgM+ aB2GPI titres (&gt;40 U/ml) all samples were also aCL IgG+ or IgM+. The percentage of aB2GPI IgG+ and/or IgM+ positive cases within the LAC positive patients increased from 43/154 (27.9%) by ELISA to 42/92 (45.7%) by CLIA (p=0.0056; 95%CI: 1.26-3.72, OR 2.17). <h3>Conclusions</h3> The CLIA method showed comparable sensitivity to ELISA for high titres samples, while improved significantly the overall aB2GPI specificity of the aCL tests and, more importantly, the correlation with LAC activity. Low positive aB2GPI IgM samples increased, probably due to the intrinsic high sensitivity of the CLIA method, suggesting a possible reformulation of the cut-off. <h3>Disclosure of Interest</h3> None declared
Longitudinal Analysis of Severe Anxiety Symptoms in the Last Year of Life Among Patients With Advanced Cancer: Relationships With Proximity to Death, Burden, and Social Support
Authors: Siew Tzuh Tang, Jen-Shi Chen, Wen-Chi Chou, Wen-Cheng Chang, Chiao-En Wu, Chia-Hsun Hsieh, Ming-Chu Chiang, Mei-Ling Kuo
Journal: Journal of the National Comprehensive Cancer Network (2016)

Background: Temporal changes in the prevalence of anxiety disorders/symptoms for patients with cancer at the end of life (EOL) remain unclear. This study was undertaken to describe changes in the prevalence of severe anxiety symptoms and to identify its correlates in the last year of life for patients with cancer. Methods: A convenience sample of 325 patients with cancer was followed until death. Severe anxiety symptoms were identified as anxiety subscale scores of 11 or greater on the Hospital Anxiety and Depression Scale. Longitudinal changes in and correlates of severe anxiety symptoms were examined from demographics, disease-related characteristics, disease burden, perceived burden to others, and social support using multivariate logistic regression modeling with generalized estimating equations. Results: The prevalence of severe anxiety symptoms increased as death approached (18.6%, 21.9%, 26.7%, and 33.4% at 181–365, 91–180, 31–90, and 1–30 days before death, respectively). However, after controlling for covariates, this temporal increase was not significant. The prevalence of severe anxiety symptoms was not associated with fixed demographics and disease-related characteristics, except for diagnosis and metastatic status, but was significantly higher in patients with cancer with high physical symptom distress, severe depressive symptoms, high perceived burden to others, and strong perceived social support. Conclusions: Severe anxiety symptoms were not associated with time proximity to death per se but were related to factors modifiable by high-quality EOL care. Clinicians may decrease the likelihood of severe anxiety symptoms at EOL by adequately managing physical and depressive symptoms and lightening perceived burden to others for patients strongly connected with their social network to improve their psychological well-being.
AB1022 Validation of Sledai-2K Modified in Patients with Childhood-Onset Systemic Lupus Erythematosus
Authors: M. Postal, N.A. Sinicato, A.T. Lapa, K.O. Peliçari, R. Marini, S. Appenzeller
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Over the past 4 decades, the prognosis of patients with systemic lupus erythematosus (SLE) has improved because of advances in the recognition from the softest to the most severe forms of the disease. The assessment of global disease activity over time can be an important predictor of mortality. <h3>Objectives</h3> Validate SLEDAI-2K modified in childhood-onset systemic lupus erythematosus (cSLE). <h3>Methods</h3> We included consecutive patients with cSLE at the Hospital of Clinics/UNICAMP. All included patients had disease diagnosis ≤18 years age. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), SLEDAI-2K, Modified SLEDAI-2K (SLEDAI-2K modified), Mexican version of SLEDAI (MEX-SLEDAI), the European Consensus Lupus Activity Measurement Index (ECLAM) and Systemic Lupus Erythematosus Disease Activity Index Modification SELENA (SELENA-SLEDAI). We evaluated 4 visits for each patient. <h3>Results</h3> We included 58 consecutive patients with cSLE (mean age 19.08±4.13). The mean follow-up time of patients was 390 patient-years. The correlation coefficients between SLEDAI, SLEDAI-2K and SELENA-SLEDAI were 1 (p&lt;0.001). Among SLEDAI and MEX-SLEDAI (r =0.83, p&lt;0.001), modified SLEDAI-2K (r =0.96, p&lt;0.001) ECLAM and (r =0.84, p&lt;0.001). Among MEX-SLEDAI and modified SLEDAI-2K (r =0.87, p&lt;0.001) and ECLAM (r =0.71, p&lt;0.001). Finally, between modified SLEDAI-2K and ECLAM the correlation coefficient was 0.78; p&lt;0.001. This direct correlation was observed in all tested visits. <h3>Conclusions</h3> The results show high correlation between the different indices, showing that the SLEDAI 2K-modified can also be used in patients with cSLE. <h3>Acknowledgements</h3> Grants: Research Support Foundation of São Paulo –FAPESP (Simone 2008/02917-0, Mariana 2011/03788-2, Aline 2013/09480-5, Nailú 2010/13637-9) CNPQ (300447/2009-4 and 471343/2011-0; 302205/2012-8; 473328/2013-5) <h3>Disclosure of Interest</h3> None declared
Diagnosis by Linear Combinations of Biochemical Values
Authors: J A Silbert
Journal: New England Journal of Medicine (1972)

To the Editor.—  The use of human semen for donor insemination has been found to be safe and efficacious. 1 When the frozen semen is stored at the temperature of liquid nitrogen, all biological activity ceases and the semen may be preserved for long periods of time. Frozen human semen has, in fact, been used successfully after ten years of storage. 2   When young men who may yet wish to have children are to undergo procedures that may decrease their fertility, prophylactic cryobanking of semen warrants serious consideration. Younger men referred for prostatic surgery, bladder neck surgery, or for radiotherapy or chemotherapy, particularly of those malignant neoplasms that have a high probability of cure (eg, seminoma, Hodgkin's disease) may find it an advantage to deposit an adequate supply for procreational use at a later date before the consequences of the treatment significantly diminish the quality of the semen.  Human semen